|Day Low/High||279.18 / 287.95|
|52 Wk Low/High||219.70 / 374.99|
Covid-19 has had a big impact on this sector, but these names have strong catalysts going into the next quarter.
The Real Money Post Industrial Average is up nearly 11% so far this quarter, beating all major indices, but valuations are looking stretched.
The markets are really in the hands of Washington right now, and Washington is in the hands of the virus.
The RMPIA rebounded more than 22% in the June quarter to finish up 7.8% at the 2020 half mark.
Let's look at the chart and see how I'd trade AA.
Let's take a close look at BIIB and arrive at a strategy for the shares.
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
A bear market, if it gets us all to slow down, may be necessary to slow the coronavirus' spread -- but this doesn't mean I'm giving up. To the contrary.
Let's check out the charts of SGMO and come up with a trading strategy.
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
It's no secret that the Fed would like to get out of the short-term repo business.
The Medical Technology Stock Letter's top pick rose 357% in 2019.
Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.
A lot of the names that fell hard after the Clinton impeachment have been record earners since then.
We're seeing lots of companies snapping up their peers, and the market is applauding.
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.
Breaking down an approach to the long side of this biotech stock.
These stocks are priced for total imperfection. That's just what you want.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.